Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

S. Rule; W. Jurczak; M. Jerkeman; C. Rusconi; M. Trneny; F. Offner; D. Caballero; C. Joao; M. Witzens-Harig; G. Hess; I. Bence-Bruckler; S. G. Cho; C. Thieblemont; W. Zhou; T. Henninger; J. Goldberg; J. Vermeulen; M. Dreyling

doi:10.1038/s41375-018-0023-2

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

S. Rule
, W. Jurczak
, M. Jerkeman
, C. Rusconi
, M. Trneny
, F. Offner
, D. Caballero
, C. Joao
, M. Witzens-Harig
, G. Hess
, I. Bence-Bruckler
, S. G. Cho
, C. Thieblemont
, W. Zhou
, T. Henninger
, J. Goldberg
, J. Vermeulen
, M. Dreyling

Department of Internal Medicine

University of Plymouth
Jagiellonian University in Kraków
Lund University
Asst Grande Ospedale Metropolitano Niguarda
Charles University
Ghent University
Hospital Clínico Universitario de Salamanca
Champalimaud Foundation
Institutto Português de Oncologia de Lisboa
Heidelberg University
Johannes Gutenberg University Mainz
University of Ottawa
Université Paris Cité
Johnson & Johnson
Ludwig Maximilian University of Munich

Research output: Contribution to journal › Article › peer-review

100 Scopus citations

Original language	English
Pages (from-to)	1799-1803
Number of pages	5
Journal	Leukemia
Volume	32
Issue number	8
DOIs	https://doi.org/10.1038/s41375-018-0023-2
State	Published - 1 Aug 2018

Bibliographical note

Funding Information:
Conflict of interest Conflicts of interestSR has served as an advisor for Janssen, Pharmacyclics and Napp, and has received research funding from Janssen. WJ has received research funding from Janssen and Pharmacyclics. MJ has received research funding from Janssen, Cel-gene, Abbvie and Gilead. CR has served as an advisor for Italfarmaco, Teva, Janssen, Takeda and Roche. MT has served as an advisor and received research funding from Janssen. CJ has served as an advisor for Celgene, Janssen, Takeda, Amgen and Roche. MW-H has served as an advisor and received honoraria from Janssen. GH has served as an advisor and received honoraria from Roche, Pfizer, Janssen, CTI and Celgene, and received research support from Roche, Pfizer, Mundipharma, Celgene and CTI. CT has served as an advisor for Bayer, Celgene, Janssen and Roche, and received research funding from Roche. MD has served as an advisor and received research funding from Janssen and Pfizer, and has received honoraria from Janssen. WZ is a contractor of Janssen. TH, JG and JV are employees of Janssen and own stocks in Johnson & Johnson. The remaining authors declare that they have no conflict of interest.

Funding Information:
Acknowledgements This study was funded by Janssen Research & Development. Writing assistance was provided by Juan Sanchez-Cortes, PhD (PAREXEL, Hackensack, NJ, USA) and Natalie Dennis (PAREXEL, Worthing, UK) and was funded by Janssen Global Services, LLC. The authors would like to thank the contribution of Mark Wildgust and Lori Parisi for their support in the long-term reporting for this study. We also thank the patients who participated in this trial, their families and the investigators and coordinators at each of the clinical sites.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41375-018-0023-2

Cite this

Rule, S., Jurczak, W., Jerkeman, M., Rusconi, C., Trneny, M., Offner, F., Caballero, D., Joao, C., Witzens-Harig, M., Hess, G., Bence-Bruckler, I., Cho, S. G., Thieblemont, C., Zhou, W., Henninger, T., Goldberg, J., Vermeulen, J., & Dreyling, M. (2018). Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia, 32(8), 1799-1803. https://doi.org/10.1038/s41375-018-0023-2

@article{a573a044ed28402ca5a6133831cd214c,

title = "Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study",

author = "S. Rule and W. Jurczak and M. Jerkeman and C. Rusconi and M. Trneny and F. Offner and D. Caballero and C. Joao and M. Witzens-Harig and G. Hess and I. Bence-Bruckler and Cho, \{S. G.\} and C. Thieblemont and W. Zhou and T. Henninger and J. Goldberg and J. Vermeulen and M. Dreyling",

note = "Funding Information: Conflict of interest Conflicts of interestSR has served as an advisor for Janssen, Pharmacyclics and Napp, and has received research funding from Janssen. WJ has received research funding from Janssen and Pharmacyclics. MJ has received research funding from Janssen, Cel-gene, Abbvie and Gilead. CR has served as an advisor for Italfarmaco, Teva, Janssen, Takeda and Roche. MT has served as an advisor and received research funding from Janssen. CJ has served as an advisor for Celgene, Janssen, Takeda, Amgen and Roche. MW-H has served as an advisor and received honoraria from Janssen. GH has served as an advisor and received honoraria from Roche, Pfizer, Janssen, CTI and Celgene, and received research support from Roche, Pfizer, Mundipharma, Celgene and CTI. CT has served as an advisor for Bayer, Celgene, Janssen and Roche, and received research funding from Roche. MD has served as an advisor and received research funding from Janssen and Pfizer, and has received honoraria from Janssen. WZ is a contractor of Janssen. TH, JG and JV are employees of Janssen and own stocks in Johnson \& Johnson. The remaining authors declare that they have no conflict of interest. Funding Information: Acknowledgements This study was funded by Janssen Research \& Development. Writing assistance was provided by Juan Sanchez-Cortes, PhD (PAREXEL, Hackensack, NJ, USA) and Natalie Dennis (PAREXEL, Worthing, UK) and was funded by Janssen Global Services, LLC. The authors would like to thank the contribution of Mark Wildgust and Lori Parisi for their support in the long-term reporting for this study. We also thank the patients who participated in this trial, their families and the investigators and coordinators at each of the clinical sites.",

year = "2018",

month = aug,

day = "1",

doi = "10.1038/s41375-018-0023-2",

language = "English",

volume = "32",

pages = "1799--1803",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "8",

}

Rule, S, Jurczak, W, Jerkeman, M, Rusconi, C, Trneny, M, Offner, F, Caballero, D, Joao, C, Witzens-Harig, M, Hess, G, Bence-Bruckler, I, Cho, SG, Thieblemont, C, Zhou, W, Henninger, T, Goldberg, J, Vermeulen, J & Dreyling, M 2018, 'Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study', Leukemia, vol. 32, no. 8, pp. 1799-1803. https://doi.org/10.1038/s41375-018-0023-2

TY - JOUR

T1 - Ibrutinib versus temsirolimus

T2 - 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

AU - Rule, S.

AU - Jurczak, W.

AU - Jerkeman, M.

AU - Rusconi, C.

AU - Trneny, M.

AU - Offner, F.

AU - Caballero, D.

AU - Joao, C.

AU - Witzens-Harig, M.

AU - Hess, G.

AU - Bence-Bruckler, I.

AU - Cho, S. G.

AU - Thieblemont, C.

AU - Zhou, W.

AU - Henninger, T.

AU - Goldberg, J.

AU - Vermeulen, J.

AU - Dreyling, M.

N1 - Funding Information: Conflict of interest Conflicts of interestSR has served as an advisor for Janssen, Pharmacyclics and Napp, and has received research funding from Janssen. WJ has received research funding from Janssen and Pharmacyclics. MJ has received research funding from Janssen, Cel-gene, Abbvie and Gilead. CR has served as an advisor for Italfarmaco, Teva, Janssen, Takeda and Roche. MT has served as an advisor and received research funding from Janssen. CJ has served as an advisor for Celgene, Janssen, Takeda, Amgen and Roche. MW-H has served as an advisor and received honoraria from Janssen. GH has served as an advisor and received honoraria from Roche, Pfizer, Janssen, CTI and Celgene, and received research support from Roche, Pfizer, Mundipharma, Celgene and CTI. CT has served as an advisor for Bayer, Celgene, Janssen and Roche, and received research funding from Roche. MD has served as an advisor and received research funding from Janssen and Pfizer, and has received honoraria from Janssen. WZ is a contractor of Janssen. TH, JG and JV are employees of Janssen and own stocks in Johnson & Johnson. The remaining authors declare that they have no conflict of interest. Funding Information: Acknowledgements This study was funded by Janssen Research & Development. Writing assistance was provided by Juan Sanchez-Cortes, PhD (PAREXEL, Hackensack, NJ, USA) and Natalie Dennis (PAREXEL, Worthing, UK) and was funded by Janssen Global Services, LLC. The authors would like to thank the contribution of Mark Wildgust and Lori Parisi for their support in the long-term reporting for this study. We also thank the patients who participated in this trial, their families and the investigators and coordinators at each of the clinical sites.

PY - 2018/8/1

Y1 - 2018/8/1

UR - https://www.scopus.com/pages/publications/85044345230

U2 - 10.1038/s41375-018-0023-2

DO - 10.1038/s41375-018-0023-2

M3 - Article

C2 - 29572505

AN - SCOPUS:85044345230

SN - 0887-6924

VL - 32

SP - 1799

EP - 1803

JO - Leukemia

JF - Leukemia

IS - 8

ER -

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

Bibliographical note

UN SDGs

Access to Document

Other files and links

Cite this